Pear Therapeutics - PEAR Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: NaN
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.00
+0 (0.00%)
Get New Pear Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PEAR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PEAR

Analyst Price Target is $0.00
This price target is based on 0 analysts offering 12 month price targets for Pear Therapeutics in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a NaN upside from the last price of $0.00.

This chart shows the closing price for PEAR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Pear Therapeutics. This rating has held steady since March 2024, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
8/23/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
11/21/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
2/19/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/19/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/17/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/15/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/14/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/13/2025

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
3/20/2023Chardan CapitalDowngradeBuy ➝ Neutral
3/20/2023Credit Suisse GroupDowngradeOutperform ➝ Neutral
3/17/2023BTIG ResearchDowngradeBuy ➝ Neutral
11/16/2022CitigroupLower TargetBuy$7.00 ➝ $5.00
11/15/2022Credit Suisse GroupLower TargetOutperform$9.00 ➝ $7.00
11/15/2022Chardan CapitalLower TargetBuy$9.00 ➝ $8.00
8/12/2022BTIG ResearchLower TargetBuy$11.00 ➝ $5.00
8/12/2022Chardan CapitalLower TargetBuy$13.00 ➝ $9.00
7/26/2022Credit Suisse GroupLower TargetOutperform$11.00 ➝ $9.00
6/24/2022BTIG ResearchLower TargetBuy$12.00 ➝ $11.00
6/16/2022Lifesci CapitalReiterated RatingOutperform
6/13/2022Chardan CapitalReiterated RatingBuy
5/17/2022Chardan CapitalLower TargetBuy$16.00 ➝ $13.00
5/17/2022CitigroupBoost TargetBuy$10.00 ➝ $11.00
3/29/2022CitigroupLower TargetBuy$13.00 ➝ $12.00
1/26/2022Bank of AmericaInitiated CoverageNeutral
1/20/2022Credit Suisse GroupInitiated CoverageOutperform$11.00
1/3/2022BTIG ResearchInitiated CoverageBuy$12.00
12/29/2021CitigroupInitiated CoverageBuy$13.00
12/22/2021Chardan CapitalReiterated RatingBuy
(Data available from 2/14/2020 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/19/2024
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/18/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
9/17/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/17/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/16/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/16/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/15/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/14/2025

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Pear Therapeutics logo
Pear Therapeutics, Inc., a commercial-stage healthcare company, develops and sells software-based medicines. Its commercial products are reSET for the treatment of substance use disorder related to alcohol, cannabis, cocaine, and stimulants; reSET-O for the treatment of opioid use disorder in combination with buprenorphine; and Somryst, a software-based treatment for chronic insomnia. The company is also developing a pipeline of 14 product candidates focusing on psychiatry, neurology, and outside of central nervous system therapeutic areas, such as gastrointestinal, oncology, and cardiovascular. Pear Therapeutics, Inc. was incorporated in 2013 and is based in Boston, Massachusetts.
Read More

Today's Range

Now: N/A

50 Day Range

MA: N/A

52 Week Range

Now: N/A

Volume

66,303,200 shs

Average Volume

7,748,841 shs

Market Capitalization

$4.17 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.45

Frequently Asked Questions

What sell-side analysts currently cover shares of Pear Therapeutics?

The following Wall Street sell-side analysts have issued research reports on Pear Therapeutics in the last twelve months:
View the latest analyst ratings for PEAR.

What is the current price target for Pear Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Pear Therapeutics in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Pear Therapeutics in the next year.
View the latest price targets for PEAR.

What is the current consensus analyst rating for Pear Therapeutics?

Pear Therapeutics currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for PEAR.

What other companies compete with Pear Therapeutics?

Other companies that are similar to Pear Therapeutics include Kindly MD, Agape ATP, Better Therapeutics, UpHealth and Vsee Health. Learn More about companies similar to Pear Therapeutics.

How do I contact Pear Therapeutics' investor relations team?

Pear Therapeutics' physical mailing address is 195 CHURCH STREET 15TH FLOOR, NEW HAVEN CT, 06510. The company's listed phone number is 617-925-7848 and its investor relations email address is [email protected]. The official website for Pear Therapeutics is peartherapeutics.com. Learn More about contacing Pear Therapeutics investor relations.